These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 21839244)

  • 1. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
    Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
    Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
    Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.
    Glowacki F; Lionet A; Buob D; Labalette M; Allorge D; Provôt F; Hazzan M; Noël C; Broly F; Cauffiez C
    Nephrol Dial Transplant; 2011 Sep; 26(9):3046-50. PubMed ID: 21677300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?
    Singh R; Srivastava A; Kapoor R; Mittal RD
    J Clin Pharmacol; 2011 Apr; 51(4):603-15. PubMed ID: 20571034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of pharmacogenetics to optimize immunosuppressive therapy.
    Macphee IA
    Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical interest of pharmacogenetic polymorphisms in the immunosuppressive treatment after heart transplantation.
    Herrero MJ; Almenar L; Jordán C; Sánchez I; Poveda JL; Aliño SF
    Transplant Proc; 2010 Oct; 42(8):3181-2. PubMed ID: 20970643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinational Effect of CYP3A5 and MDR-1 Polymorphisms on Tacrolimus Pharmacokinetics in Liver Transplant Patients.
    Buendía JA; Otamendi E; Kravetz MC; Cairo F; Ruf A; de Davila M; Powazniak Y; Nafissi J; Lazarowski A; Bramuglia G; Villamil F
    Exp Clin Transplant; 2015 Oct; 13(5):441-8. PubMed ID: 26450467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
    Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
    Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pharmacogenetic polymorphisms in routine immunosuppression therapy after renal transplantation.
    Herrero MJ; Sánchez-Plumed J; Galiana M; Bea S; Marqués MR; Aliño SF
    Transplant Proc; 2010 Oct; 42(8):3134-6. PubMed ID: 20970628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients.
    Mendes J; Martinho A; Simoes O; Mota A; Breitenfeld L; Pais L
    Transplant Proc; 2009 Apr; 41(3):840-2. PubMed ID: 19376366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
    Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
    Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients.
    Onizuka M; Kunii N; Toyosaki M; Machida S; Ohgiya D; Ogawa Y; Kawada H; Inoko H; Ando K
    Bone Marrow Transplant; 2011 Aug; 46(8):1113-7. PubMed ID: 21102498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study.
    Musuamba FT; Mourad M; Haufroid V; Delattre IK; Verbeeck RK; Wallemacq P
    Ther Drug Monit; 2009 Dec; 31(6):734-42. PubMed ID: 19855314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients.
    Wei-lin W; Jing J; Shu-sen Z; Li-hua W; Ting-bo L; Song-feng Y; Sheng Y
    Liver Transpl; 2006 May; 12(5):775-80. PubMed ID: 16628701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.